On September 18, 2023, Simmunome announced it secured $2 million in a pre-seed funding round led by Theodorus Investment Funds. The round also had participation from Fonds d’investissement Eurêka, BKR Capital, Sandpiper Ventures, and ACET Capital.
Simmunome is an artificial intelligence company that focuses on predicting the result of clinical trials.
Osler, Hoskin & Harcourt LLP advised with a team consisting of Shahir Guindi, Calvin Leung and Yulia Yugay (Emerging and High Growth Companies).